Marine Drugs (Apr 2022)

The Emerging Evidence for a Protective Role of Fucoidan from <i>Laminaria japonica</i> in Chronic Kidney Disease-Triggered Cognitive Dysfunction

  • Zhihui Ma,
  • Zhiyou Yang,
  • Xinyue Feng,
  • Jiahang Deng,
  • Chuantong He,
  • Rui Li,
  • Yuntao Zhao,
  • Yuewei Ge,
  • Yongping Zhang,
  • Cai Song,
  • Saiyi Zhong

DOI
https://doi.org/10.3390/md20040258
Journal volume & issue
Vol. 20, no. 4
p. 258

Abstract

Read online

This study aimed to explore the mechanism of fucoidan in chronic kidney disease (CKD)-triggered cognitive dysfunction. The adenine-induced ICR strain CKD mice model was applied, and RNA-Seq was performed for differential gene analysis between aged-CKD and normal mice. As a result, fucoidan (100 and 200 mg kg−1) significantly reversed adenine-induced high expression of urea, uric acid in urine, and creatinine in serum, as well as the novel object recognition memory and spatial memory deficits. RNA sequencing analysis indicated that oxidative and inflammatory signaling were involved in adenine-induced kidney injury and cognitive dysfunction; furthermore, fucoidan inhibited oxidative stress via GSK3β-Nrf2-HO-1 signaling and ameliorated inflammatory response through regulation of microglia/macrophage polarization in the kidney and hippocampus of CKD mice. Additionally, we clarified six hallmarks in the hippocampus and four in the kidney, which were correlated with CKD-triggered cognitive dysfunction. This study provides a theoretical basis for the application of fucoidan in the treatment of CKD-triggered memory deficits.

Keywords